(+)-Magnoflorine suppresses osteoclastogenesis by regulating CCDC88A-associated signaling networks in estrogen-deficient osteoporosis.
GNS effectively alleviated estrogen deficiency-associated bone loss by suppressing osteoclast activation and highlight GNS-derived compounds as potential therapeutic candidates for postmenopausal osteoporosis.